Specialty CROs

Preclinical ADME and pharmacokinetics CRO in Pennsylvania providing in vitro and in vivo absorption, distribution, metabolism, and excretion studies as part of Pharmaron's global network.

Exton, Pennsylvania-based preclinical CRO providing in vivo PK/PD studies, ADME services, and GLP bioanalytical testing for small-molecule and biologic drug candidates.

San Diego-based preclinical CRO providing in vitro ADME screening, permeability assays, and metabolic stability studies for drug discovery programmes.

Italian preclinical CRO providing GLP safety pharmacology, general and genetic toxicology, DMPK, and bioanalytical services from Nerviano (Milan) facilities.

Leading IRB, IACUC, and consulting services provider for clinical and preclinical research, plus site management and performance optimization services.

Frankfurt-based specialty CRO focusing on endocrinology and oncology clinical development with strong European regulatory expertise.

Riyadh-based Saudi CRO providing clinical trial management, regulatory consulting, and pharmacovigilance services across the GCC region with SFDA regulatory expertise.

Canadian specialty CRO focused exclusively on gastrointestinal disease clinical trials with proprietary central reading and histopathology services for IBD and liver disease.

Gainesville, Florida-based dermatology and wound care CRO providing Phase I-IV clinical trials, photoprotection testing, and clinical pharmacology services for topical drug products.

UK nonclinical safety CRO founded by former AstraZeneca scientists, specializing in integrated toxicology and ion channel electrophysiology studies for regulatory drug safety assessment.

French CRO providing Phase I-III clinical trial management and monitoring services across France and Western Europe, with expertise in rare disease and orphan drug development.

Nantes-based French CRO specialising in CNS, sleep medicine, and neuroscience clinical trials with proprietary EEG/PSG expertise and Phase I-II clinical pharmacology capabilities.

Phase I-III oncology CRO providing clinical trial management with deep oncology expertise for small and mid-size pharma and biotech sponsors.

Global CRO built exclusively for MedTech, integrating regulatory strategy, clinical development, and market access reimbursement for device and IVD programs from the Netherlands since 1988.

Clinical pharmacology and bioanalytical CRO providing Phase I studies, bioequivalence, and PK/PD studies from a purpose-built 150-bed clinical pharmacology unit in Dilworth, Minnesota.

Singapore-based specialty CRO providing preclinical pharmacology, toxicology, and early clinical development services with particular expertise in biologics and biosimilar characterization.

Dhaka-based CRO providing clinical trial management and bioequivalence studies for Bangladesh's pharmaceutical industry, one of the largest generic drug markets in South Asia.

Italian CRO providing Phase I clinical pharmacology studies including bioequivalence, food-effect, and drug interaction trials from its dedicated Phase I unit in Milan.

Independent nonprofit applied science and technology organization providing preclinical research, inhalation toxicology, bioanalytical services, and pharmaceutical development support.

World's largest nonprofit R&D organization offering GLP-compliant preclinical safety, toxicology, inhalation studies, and bioanalytical services including BSL-3 biocontainment capabilities.

Osaka-based clinical CRO specializing in medical device and diagnostic clinical trials in Japan, providing regulatory consulting, site management, and data management services under PMDA guidelines.

Canadian Phase I and bioequivalence CRO with a 150-bed clinical facility in Toronto and over 2,500 completed BA/BE and early-phase studies for global pharma clients.

Indian medical imaging and cardiac safety CRO providing centralized ECG reading, imaging endpoint adjudication, and eClinical technology services for global clinical trials.

Lithuanian regulatory affairs consultancy providing EU regulatory strategy, marketing authorisation applications, pharmacovigilance, and medical writing across 30+ European markets.

UK-based specialist oncology CRO providing early-phase clinical trial management, tumour genomics, and biomarker-driven trial design for immuno-oncology programmes.

Nigerian contract research organisation providing clinical trial support, site management, data management, and regulatory affairs services for pharmaceutical sponsors in West Africa.

Transatlantic Phase 1 CRO with clinical pharmacology units in Rennes (France) and Newark (NJ, USA). Specializes in first-in-human, CNS, cardiac safety, and abuse liability studies.

Buenos Aires-based CRO providing Phase II-IV clinical trial management across Argentina, with strong site networks in cardiology, endocrinology, and rheumatology.

Regulatory affairs and clinical development consultancy providing full-service FDA/EMA submission support, pharmacovigilance, and clinical trial management for small pharma and biotech.

Independent early-phase CRO in the Netherlands specializing in first-in-human and Phase I trials using innovative biomarkers, with a purpose-built 54-bed clinical research unit adjacent to Leiden University Medical Center.

Accra-based Ghanaian CRO specializing in vaccine clinical trials and infectious disease research across West Africa, with established relationships with WHO and GAVI-funded programs.

Adelaide-based Phase 1 clinical pharmacology unit conducting first-in-human, bioequivalence, and biosimilar studies. Operates a 150-bed facility at the Royal Adelaide Hospital campus.

Istanbul-based Turkish CRO offering clinical project management, site monitoring, regulatory submissions, and pharmacovigilance services across Turkey and the Balkans.

Ho Chi Minh City-based Vietnamese CRO providing Phase II-IV clinical trial management, BA/BE studies, and regulatory consulting for pharmaceutical companies entering the Vietnamese market.

Swiss independent Phase I and early-phase clinical CRO in Basel with a dedicated 24-bed clinical pharmacology unit, specializing in first-in-human studies for oncology, cardiovascular, and CNS compounds.

Swedish CRO with a 12-bed first-in-human research unit at Uppsala University Hospital, specializing in Phase I and Phase II trials with approximately five FIH studies annually.

Preclinical CRO in Pennsylvania providing GLP and non-GLP toxicology, safety pharmacology, and pathology services with a focus on small and large molecule therapeutics.

US-based site management organisation providing clinical trial site identification, feasibility, start-up, and monitoring services for pharma and biotech sponsors.

Italy-based CRO specialising in cardiovascular safety pharmacology and cardiac ion channel testing with proprietary automated patch-clamp platforms.

Specialized early clinical research CRO providing Phase I clinical pharmacology, bioanalytical, and ADME services from dedicated clinical units.

Swiss clinical pharmacology unit specialising in first-in-human Phase I trials, PK/PD studies, and early-phase bioequivalence studies for small molecules and biologics.

Global precision medicine CRO delivering biomarker and bioanalytical services including flow cytometry, histopathology, proteomics, and genomics for clinical trials.

Santiago-based Phase I clinical pharmacology unit providing first-in-human, BA/BE, and pharmacokinetic studies for Latin American and international sponsors under ICH-GCP standards.

Biosimulation and regulatory science company providing model-informed drug development, regulatory science consulting, and software solutions for the pharmaceutical industry.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.

Specialty CRO focused on translational oncology services. Champions provides patient-derived xenograft (PDX) tumor models, ex vivo tumor platforms, and oncology pharmacology studies.

Preclinical oncology CRO using patient-derived tumor models and TumorGraft technology for in vivo efficacy studies, providing translational research services for oncology drug development.

Shanghai-headquartered CRO/CDMO offering integrated drug discovery chemistry, biology, and biologics development services including ADC and recombinant protein production.

Global clinical trial technology and endpoint services company providing cardiac safety (ECG), respiratory, imaging, patient-reported outcomes, and clinical event adjudication for pharma and biotech sponsors.

Europe's first specialist CRO dedicated to psychedelic compound clinical research, providing full-service trial design and execution for novel psychiatric treatments in the UK.

Mexico City-based CRO specializing in CNS and psychiatry clinical trials across Latin America, with established investigator networks in Mexico, Colombia, and Chile.

Indian CRO providing clinical data management, biostatistics, pharmacovigilance, and medical writing services for global pharmaceutical and biotech companies at competitive costs.

Delhi-based Indian CRO providing regulatory and clinical trial management services across pharma, medical devices, and nutraceuticals.

Clinical technology company providing eCOA, eConsent, and clinical data capture solutions integrated with CRO-like trial management capabilities for decentralized and hybrid clinical trials.

Bangalore-based CRO subsidiary of Biocon offering early-phase clinical trials, bioequivalence studies, bioanalytical testing and Phase II-IV services with expertise in biosimilars.

The only global full-service CRO focused exclusively on CNS drug development, with involvement in 22 FDA-approved CNS therapies across 13 indications.

New York-based Phase I CRO operating an 80-bed clinical pharmacology unit for first-in-human, CNS, cardiac safety, and abuse liability studies.

Pennsylvania-based dermatology and aesthetics specialty CRO providing Phase I-IV clinical trial management and site services for topical, injectable, and device-based products.

Lahore-based Pakistani CRO providing Phase II-IV clinical trial management, BA/BE studies, and pharmacovigilance services with access to Pakistan's large treatment-naive patient populations.

Novotech's dedicated Phase I research unit in Sydney providing first-in-human, SAD/MAD, food effect, and bioavailability studies with a 30-bed clinical pharmacology facility.

Adelaide-based Australian Phase I clinical pharmacology unit within the Royal Adelaide Hospital, conducting first-in-human, BA/BE, and cardiac safety studies with a 48-bed facility.

Specialty CRO focused exclusively on CNS clinical trials, neurocognitive endpoint assessments, and central rater training for Phase I-III neuropsychiatric studies.

GLP-compliant preclinical CRO specializing in toxicology, pathology, and ADME studies for pharmaceutical, biotech, and agrochemical clients with full necropsy and histopathology capabilities.

Full-service clinical CRO providing Phase I-IV development support with emphasis on bioanalytical services, clinical pharmacology, and PK/PD modeling from their Salt Lake City operations.

US-based clinical-stage CRO arm specialising in endocrinology and cortisol-modulation therapeutics with expertise in Phase I-III metabolic and CNS clinical trials.

Labcorp Drug Development's Chinese laboratory providing preclinical safety assessment, bioanalytical services, and clinical trial support for NMPA regulatory submissions.

Labcorp's early development and Phase 1 clinical unit operating dedicated clinical pharmacology facilities. Provides first-in-human, bioavailability/bioequivalence, and thorough QT studies.

Labcorp Drug Development's UK preclinical facility providing GLP toxicology, safety pharmacology, and reproductive toxicology studies from Harrogate, North Yorkshire.

Labcorp Drug Development's Harrogate facility providing preclinical toxicology, pathology, and safety assessment services with large-animal capabilities for IND-enabling studies.

Labcorp Drug Development's Japanese operations providing preclinical safety assessment, bioanalytical services, and clinical trial support for regulatory submissions to PMDA and other Asian regulatory agencies.

LabCorp Drug Development preclinical and toxicology centre in Madison, Wisconsin, providing GLP-compliant general and genetic toxicology, safety pharmacology, and reproductive toxicology studies.

US-based CRO specializing in rare disease and pediatric clinical trials, providing end-to-end trial management with deep expertise in orphan drug development and regulatory strategy.

Belgrade-based Serbian CRO providing clinical trial management, monitoring, and regulatory support for Phase II-IV studies across the Western Balkans region.

Translational oncology and metabolic disease CRO providing tumor models (PDX, syngeneic, humanized), oncology pharmacology, and biomarker services for drug discovery.

Biostatistics-focused CRO and software company pioneering adaptive trial design, group sequential methods, and clinical trial simulation for pharma and biotech.

Indian CRO affiliated with Dabur offering preclinical drug discovery, IND-enabling studies, and non-clinical research services from facilities near Delhi.

San Diego-based CRO specialising in dermatology clinical trials with proprietary non-invasive skin sampling technology for melanoma and inflammatory skin disease studies.

Chinese CRO-turned-biotech providing clinical development services with deep oncology expertise, operating a portfolio of discovery through Phase III programs in solid tumors and hematological malignancies.

Turkish-German CRO providing Phase I-III clinical trial management, biostatistics, and regulatory consulting with focus on bridging European and Turkish markets.

French preclinical CRO based in Lyon evaluating efficacy and safety of new compounds including drugs, biologics, and medical devices across innovative in-vitro and in-vivo models.

Melbourne-based CRO specializing in Phase I-IIa first-in-human studies, offering rapid trial startup under Australia's CTN scheme with access to leading Australian clinical pharmacology units.

Research models and services provider offering genetically defined laboratory animals, contract research services, and scientific consulting for preclinical drug development.

Hamburg-based dermatology specialty CRO established in 1992, providing regulatory consulting and Phase I-IV clinical trial management for pharmaceutical, device, and cosmetic dermatology products.

Global real-world evidence and outcomes research firm providing observational studies, health economics, market access, and regulatory evidence generation for pharma and biotech.

Shanghai-based preclinical CRO providing in vivo pharmacology, toxicology, DMPK, and bioanalytical services with specialized PDX platforms for oncology drug development.

Drug discovery and development company offering a range of discovery and preclinical services including target validation, hit identification, lead optimization, and ADME/PK.

Specialty CRO providing GLP-compliant anatomic pathology, histotechnology, and immunohistochemistry services for pharma, biotech, and government preclinical research programs.

Specialist preclinical ophthalmology CRO with AAALAC-accredited labs in Oklahoma City and Ann Arbor, providing pharmacology, PK/tox, bioanalysis, and formulation services for ocular drug development.

Munich-based specialty CRO focused on medical device and in vitro diagnostic clinical studies, providing regulatory consulting, study monitoring, and clinical evaluation reports across Europe.

Croatian integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, and preclinical development services, now part of Polish CRO Selvita Group.

Zagreb-based drug discovery CRO (Selvita Group) providing integrated medicinal chemistry, ADME/PK, and in vitro biology services for hit-to-lead and lead optimization programs.

Texas-based Phase I clinical research unit specialising in early-phase, first-in-human, and healthy volunteer studies with integrated bioanalytical capabilities.

German regulatory affairs consultancy providing EU regulatory strategy, marketing authorisation applications, and scientific advice for pharmaceutical and biotech sponsors.

Mexico City-based CRO and leading provider of decentralised clinical trial home visit services, patient recruitment, and community research site networks across 22 Latin American countries.

Life science regulatory and clinical development consultancy specialising in regulatory strategy, quality management, and organisational support for biotech and pharma.

London-based early phase CRO conducting Phase 1 healthy volunteer and patient studies. Operates a dedicated clinical pharmacology unit at the Cumberland Business Park with 100+ bed capacity.

Chinese CRO and CDMO offering integrated preclinical biology, in-vitro pharmacology, and early drug discovery services for domestic and multinational pharma clients.

Phase I clinical research unit in New Jersey providing first-in-human, food effect, bioequivalence, and early-phase pharmacokinetic studies for pharmaceutical sponsors.

Kentucky-based preclinical CRO specialising in oncology efficacy studies using proprietary humanised rodent models and patient-derived xenografts for immuno-oncology drug development.

ICON's dedicated early development division operating clinical pharmacology units in the US and Europe, conducting first-in-human, PK/PD, food effect, and drug interaction studies.

Independent not-for-profit preclinical CRO offering full IND-enabling GLP toxicology programs, inhalation toxicology, and immunogenicity testing from the Illinois Institute of Technology campus.

Clinical research division of South Korea's Ildong Pharmaceutical group, conducting domestic and international Phase I-IV studies with access to major Korean academic medical centres.

Retina-specialty CRO with offices across Latin America, Asia, and Australia supporting clinical trials in 18+ countries for ophthalmic and rare disease indications.

Inotiv's preclinical facility in Boulder, Colorado, providing GLP toxicology, safety pharmacology, and DMPK studies with capabilities in cardiovascular, respiratory, and CNS safety assessment.

Employee-owned Canadian scientific and regulatory toxicology consultancy with 35+ years advising FDA, EMA, and Health Canada submissions for pharma, biotech, and chemical companies.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

Chinese preclinical CRO providing GLP-compliant safety evaluation, pharmacokinetics, efficacy studies, and drug metabolism studies with comprehensive NHP and rodent capabilities.

Therapeutically specialized CRO focused on CNS, cardio-metabolic, renal, and rare disease trials, providing end-to-end CRO and SMO services across 39 countries with 220,000+ subjects enrolled.

Kobe-based Japanese CRO and research institute specializing in preclinical safety assessment, pharmacology and drug metabolism studies with GLP-accredited facilities.

US-Korea bridge CRO providing early-phase clinical and regulatory services tailored for Korean life science companies entering the US FDA pathway.

Stockholm-based Nordic CRO providing clinical trial management, biostatistics, and regulatory support for Phase I-IV studies across Scandinavian countries with EMA and FDA regulatory experience.

Perth-based clinical trial site and CRO specializing in Phase 1–3 studies across multiple therapeutic areas. Located at the Harry Perkins Institute of Medical Research.

Phase I-III CRO and integrated research site network specialising in CNS, pain, obesity, and metabolic disease with wholly-owned clinical units in California.

Not-for-profit preclinical CRO with ABSL-3 capabilities and expertise in inhalation toxicology, pulmonary delivery, and infectious disease models from 100+ acre campus.

French clinical-stage gene therapy company and CRO specializing in CNS gene therapy development, providing clinical trial management for rare neurological diseases.

Japanese digital health and clinical research subsidiary of M3 Inc., leveraging its physician panel of 300,000+ doctors for clinical trial site identification and recruitment in Japan.

UK-based Phase I-IV site network and CRO operating multiple dedicated clinical research centres across Northern England for healthy volunteer and patient population studies.

European specialist CRO and regulatory consultancy for IVD and medical device companies, with IVDR and MDR expertise across offices in Lisbon, London, Barcelona, and Madrid.

Large preclinical CRO in Michigan acquired by Charles River Laboratories, providing GLP toxicology, safety pharmacology, and ADME studies in purpose-built facilities spanning over 800,000 sq ft.

Vietnam's dedicated CRO/SMO founded by Japan's SRD Group, applying Japanese GCP expertise to support clinical trials at Vietnamese research hospitals.

Dhaka-based clinical data management and biostatistics CRO providing remote monitoring, data entry, and statistical analysis services for global pharmaceutical clinical trials.

Oncology CRO founded by oncology thought-leaders specializing in Phase I and II immuno-oncology trials in North America and Europe.

Australian not-for-profit pharmaceutical company developing and registering medicines for neglected tropical diseases, providing regulatory and clinical development services for global health products.

Australian boutique CRO specialising in early-phase and first-in-human MedTech clinical trials across Australia, New Zealand, and the USA.

Boulder-based biologic discovery CRO integrating antibody discovery, protein engineering, function-first screening, and early developability assessment for complex biotherapeutics.

Full-continuum preclinical CRO providing integrated in vitro and in vivo services including efficacy, toxicity, biodistribution, and product release studies in small and large animals.

Danish biomarker CRO specializing in neoepitope biomarker technologies for tissue remodeling, conducting clinical trials in rheumatology, musculoskeletal, and metabolic disease with CAP-accredited laboratories.

Israel-based CRO with deep expertise in the Israeli pharmaceutical, medical device, and healthcare industry delivering clinical trial management for international sponsors.

Preclinical CRO specializing in in vitro pharmacology, receptor binding, enzyme inhibition assays, and ADME screening for drug discovery programs.

Hanover, Maryland-based drug screening CRO offering high-throughput receptor binding, enzyme inhibition, and functional cell-based assays for hit-to-lead optimisation programmes.

Asia-Pacific specialist CRO providing full-service clinical development capabilities with deep expertise in the Asia-Pacific regulatory landscape.

Leading Australian Phase 1 clinical trials unit operating in Melbourne, Brisbane, and Minneapolis. Specializes in first-in-human, oncology Phase 1, and healthy volunteer studies with rapid enrollment timelines.

US arm of Australian CRO Nucleus Network, operating early phase clinical trials from their Minneapolis facility. Provides Phase 1 studies with access to diverse patient populations.

Clinical pharmacology consulting firm specializing in PK/PD modeling, dose optimization, biosimilar development strategy, and regulatory science for pharmaceutical and biotech companies.

Regulatory consulting firm providing IND/NDA/BLA submission strategy, CMC consulting, and FDA interaction management for biotech and pharmaceutical sponsors.

European preclinical CRO in Dijon, France, specializing in oncology, inflammation, and infectious disease drug discovery including targeted radiotherapy programs.

German preclinical oncology CRO providing patient-derived xenograft models, ex vivo tumor assays, and in vivo efficacy studies for oncology drug development programs.

New Zealand's leading late-phase clinical research organisation delivering Phase III-IV trial results at speed and scale for global sponsors.

World's leading ophthalmology-specialized CRO providing full-service clinical development from Phase I through Phase IV exclusively for ophthalmic therapeutics, devices, and surgical products.

Independent New Zealand clinical research company conducting Phase I-IV trials with specialist early-phase capabilities and access to New Zealand's rapid ethics approval system.

Belgium-based specialty CRO focused on epidemiology and vaccine development with local hubs in South Africa, Ghana, Kenya, and Morocco, having conducted 500+ studies in 20+ African countries.

Cambridge-based specialty CRO focused on biostatistics, statistical programming, clinical data management, and regulatory submission support for pharma and biotech.

Specialty preclinical CRO focused on Asia-Pacific markets, providing preclinical safety assessment, pharmacology, and bioanalytical services for small molecule and biologic programs.

European CRO providing preclinical contract research services including in vivo pharmacology, toxicology, and bioanalytical testing from GLP-certified European facilities.

Australian pharmaceutical research company providing preclinical and clinical development services with expertise in inflammatory bowel disease and gastrointestinal therapeutic areas.

Regulatory affairs and medical writing CRO providing IND/NDA/BLA preparation, regulatory strategy, and clinical documentation support for pharmaceutical and biotech companies.

Clinical data management and biometrics CRO specializing in biostatistics, statistical programming, and data management for small to mid-size pharmaceutical and biotech companies.

Danish CRO focused on Scandinavian and Nordic clinical trial management, site selection, and regulatory submissions for pharma and medical device sponsors.

Taipei-based drug development company and CRO specializing in oncology, running Phase I-III clinical trials for new cancer therapies and out-licensing proprietary pipeline assets.

Global regulatory affairs and drug development consulting firm providing IND/NDA/MAA filing support, clinical development strategy, and pharmacovigilance services.

Australian CRO helping global pharma and biotech leverage the regulatory and cost advantages of clinical trials in Australia and New Zealand.

European regulatory affairs and pharmacovigilance services provider offering end-to-end regulatory strategy, submission management, and post-authorization compliance for pharma and biotech companies.

Israeli biotech CRO specializing in preclinical efficacy models for wound healing, dermatology, and fibrosis, providing contract research services with proprietary animal models and histopathology analysis.

Nordic preclinical CRO providing in vivo pharmacology, efficacy, and safety studies with expertise in metabolic disease, inflammation, and fibrosis models using rodent species.

Award-winning specialist biometrics CRO headquartered in London, providing biostatistics, statistical programming, data management, and analytics to global pharma, biotech, and device companies.

Preclinical CRO providing GLP-compliant safety assessment services including general toxicology, developmental and reproductive toxicology, and carcinogenicity studies.

Clinical research site in Phoenix conducting Phase I-IV clinical trials with particular strength in CNS, pain, and metabolic disease studies with rapid enrollment capabilities.

Specialty preclinical CRO focused on non-GLP ophthalmic and oncology efficacy studies, providing in vivo animal model services for ocular disease and solid tumor drug development.

Specialty CRO focused on oncology and rare disease with 2,000+ professionals, known for biomarker-driven trial design, companion diagnostics, and translational research services.

Multi-site clinical research organization conducting Phase I-IV trials with a network of dedicated research sites across the upper Midwest specializing in diverse therapeutic areas.

Global regulatory consulting, pharmacovigilance, and clinical research organization providing single-source regulatory strategy, compliance, and medical information services.

Specialty CRO focused on cardiometabolic clinical trials. Operates Phase 1–2 studies for obesity, diabetes, NASH/MASH, and cardiovascular endpoints with proprietary biomarker platforms.

Preclinical CRO specializing in CNS drug discovery using proprietary AI-powered behavioral phenotyping platforms for neurological and psychiatric disorders.

Brisbane-based Phase 1 clinical trial unit specializing in first-in-human, pharmacokinetic, and vaccine studies. Operates a dedicated clinical pharmacology unit at QIMR Berghofer campus.

Privately owned Israeli CRO providing clinical trial services for pharmaceutical and medical device companies targeting the Israeli market.

Specialty CRO providing GLP toxicology testing, biocompatibility evaluation, and analytical chemistry services for medical devices, combination products, and pharmaceutical excipients.

One of the world's largest data-focused biometrics CROs, providing biostatistics, statistical programming, clinical data management, and medical writing without conducting clinical operations.

Translational pharmaceutics CRO integrating drug substance, drug product, and clinical testing in a single facility. Specializes in formulation development with integrated Phase 1 studies.

MedTech CRO formed by the 2020 merger of Regulatory and Quality Solutions and Maetrics, delivering 40+ years of medical device regulatory, clinical, laboratory, and reimbursement expertise.

Specialty CRO providing biochemical and cell-based assay services for drug discovery. Known for kinase profiling, epigenetic screening, and custom assay development.

Oklahoma-based early-phase clinical research site specialising in Phase I healthy volunteer studies, PK/PD trials, and bioequivalence studies.

London-based Phase 1 clinical research unit specializing in early phase clinical trials, pharmacokinetics, and healthy volunteer studies. Located at Guy's Hospital campus.

Vietnam's first locally established and Ministry of Health-approved CRO providing clinical trial management and site support across Vietnamese hospitals.

Japanese preclinical CRO providing GLP safety assessment, pharmacokinetics, and toxicology studies with specialized NHP and inhalation toxicology capabilities from facilities in Japan and the US.

US subsidiary of Shin Nippon Biomedical Laboratories specializing in GLP preclinical safety assessment including general toxicology, reproductive toxicology, and inhalation studies with NHP and rodent capabilities.

Nairobi-based East African CRO providing Phase II-III clinical trial management and site coordination for infectious disease, vaccine, and maternal health studies across Kenya, Uganda, and Tanzania.

ISO 9001-certified Nigerian CRO with offices in Lagos and Nairobi specialising in Phase III-IV clinical trials, pharmacovigilance, and regulatory affairs across Africa.

Denmark-based GLP preclinical CRO offering safety pharmacology, general toxicology, reproductive toxicology, and ADME studies, known for rodent and non-rodent capabilities including minipig models.

Decentralized CRO enabling fully virtual and hybrid clinical trials through a proprietary Metasite platform, reducing site burden and improving patient access.

Sydney-based Phase 1 clinical pharmacology unit specializing in first-in-human studies, bioequivalence, and healthy volunteer trials. Part of the Novotech group.

Polish integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, computational chemistry, and preclinical services with 1,000+ scientists across Europe.

One of China's earliest chemistry-focused CROs offering integrated drug discovery, DMPK, and pharmaceutical development services globally.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

US-based early phase CRO specializing in cardiac safety (thorough QT/QTc) studies, abuse deterrent formulation, and human abuse liability studies. Operates a 120-bed clinical facility.

Munich-based specialty CRO providing biostatistics, statistical programming, and data science services for pharmaceutical, biotech, and medical device clinical trials.

Hyderabad-headquartered pharmaceutical CRO with dedicated clinical trials division providing drug discovery, early-phase clinical, and regulatory support with strong CNS expertise.

Specialty CRO with 20+ years of dermatology, aesthetics, gastroenterology, and inflammation clinical trial expertise across the US, Europe, and Australia.

Seoul-based niche CRO specializing in dermatology and cosmetic clinical trials, providing IRB-approved study design, site management, and regulatory filing for K-beauty and pharmaceutical skincare products.

Ahmedabad-based mid-size CRO providing Phase I-IV clinical trials, bioequivalence studies, and bioanalytical services to Indian and global generic pharma companies.

Bangalore-based CRO specialising in medical device clinical validations, nutraceutical studies, and Phase I-IV pharmaceutical trials across India.

Consulting arm of Syneos Health providing commercial and regulatory advisory, launch planning, and market access strategy for pharmaceutical and biotech clients.

Prague-based dedicated clinical trial site providing centralized patient recruitment and Phase II-IV trial conduct for global sponsors, part of the Synexus (now Acurian) network of research sites.

New Jersey-based dermatology and personal care CRO conducting clinical trials, product testing, and consumer perception studies for pharmaceutical, cosmetic, and OTC skincare products.

Full-service oncology-focused CRO with 40+ years managing early-phase oncology studies for the National Cancer Institute and biopharma sponsors.

South Korean genomics and CRO company providing next-generation sequencing, genomic analysis, and precision medicine research services alongside clinical biomarker and pharmacogenomics programs.

Fully integrated dermatology-dedicated CRO providing nonclinical through Phase III development services exclusively for skin disease products since 1997.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.

Preclinical neuroscience CRO spun out of GlaxoSmithKline in 2010, specializing in in vivo CNS pharmacology models for psychedelic compound and neurodegeneration research.

Medical writing and regulatory consulting CRO providing clinical study reports, investigator brochures, CTD modules, and submission documents for FDA and EMA regulatory filings.

West Africa-based CRO providing streamlined and cost-effective clinical trial solutions to global CROs, pharmaceutical, and medical device companies operating in Africa.

Indian CRO providing Phase I clinical pharmacology, bioanalytical services, and bioequivalence studies from a 230-bed clinical pharmacology unit in Ahmedabad with USFDA and EMA track record.

Netherlands-based CRO providing Phase I clinical pharmacology, bioequivalence, and early-phase clinical trial services as the European arm of India's Veeda Group.

Integrated clinical research site organization operating 20+ dedicated research sites across the US, providing high-quality Phase I-IV clinical trial execution with rapid patient enrollment.

Clinical-stage diagnostics and genomic testing company providing companion diagnostic development and biomarker-driven clinical trial services.

Innovation CRO purpose-built for medical device and IVD development, delivering integrated regulatory, clinical, and laboratory services across cardiovascular, neurological, and ophthalmic indications.

Specialized biometrics and regulatory CRO providing biostatistics, data management, medical writing, and regulatory strategy for pharmaceutical and biotech companies seeking FDA and EMA approvals.

Tech-enabled next-generation CRO offering faster and lower-cost clinical trials powered by proprietary software, targeting biotech sponsors in dermatology, oncology, and ophthalmology.

UK-based specialist CRO for ophthalmic and contact lens clinical trials, providing study design, clinical monitoring, and regulatory support for eye care medical devices and pharmaceutical products.

Chinese CRO/CDMO providing integrated drug discovery services including structure-based drug design, medicinal chemistry, ADME/PK studies, and biologics development from Shanghai operations.

Fully independent European preclinical CRO in Madrid delivering GLP-certified toxicology and safety studies aligned with EMA and FDA regulatory requirements.

Leading provider of clinical trial solutions including IRB/ethics review, site performance optimization, data analytics, and clinical trial management services for the pharmaceutical industry.

Specialty ADME/PK CRO providing in vitro and in vivo drug metabolism and pharmacokinetic studies. Known for comprehensive ADME characterization using human and animal tissues.

Kansas City-based in vitro ADME and drug metabolism CRO providing hepatocyte-based assays, enzyme induction/inhibition studies, and metabolite identification services.

South Korean pharmaceutical research institute providing preclinical safety assessment, ADME/PK studies, and efficacy testing from GLP-certified facilities in Seoul.

CRO purpose-built for first-in-human clinical trials for MedTech, biopharma, and radiopharma startups across Latin America, operating in 10 countries.

World leader in human challenge trials for infectious and respiratory diseases, operating from a purpose-built quarantine facility in London with 14+ validated infection models for RSV, influenza, and COVID-19.